Antibodies for
Immunohistochemistry
Cytokeratin 14 (LL002)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45197 IMPATH Cytokeratin 14 RTU M (LL002)
50 Tests
44266 Cytokeratin 14 RTU M (LL002)
7 ml Ready To Use
44553 Cytokeratin 14 0,1 M (LL002)
100 µl liquid Concentrated
44554 Cytokeratin 14 1 M (LL002)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Squamous Cell Carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
3
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
The cytokeratin14 gene encodes a member of the keratin family, the most diverse group of intermediate filaments. This gene product, a type I
(acidic) keratin, is usually found as a heterotetramer with two keratin 5 molecules, keratin 5 being a type II (basic) keratin. Together they form the
cytoskeleton of epithelial cells. Mutations in the genes for these keratins are associated with epidermolysis bullosa simplex. Cytokeratin 14 (CK
14) is a 50 kD polypeptide found in basal cells of squamous epithelia, some glandular epithelia, myoepithelium, and mesothelial cells.
Anti-CK 14 has been demonstrated to be useful in differentiating squamous cell carcinomas from other epithelial tumors, particularly those which
are poorly differentiated; it may be used in combination with antibodies against p63 and CK 5&6. Anti-CK 14 is one of the specific basal markers
for distinguishing between basal and nonbasal subtypes of breast carcinomas. Anti-CK 14 is also a good marker for differentiation of intraductal
from invasive salivary duct carcinoma by the positive staining of basal cells surrounding the in-situ neoplasm as well as for differentiation of
benign prostate from prostate carcinoma. Furthermore, this antibody has been useful in separating oncocytic tumors of the kidney from its renal
mimics, and in identifying metaplastic carcinomas of the breast.
Prostate: Malignant vs. Benign
CK 14
PSA/PSAP Androgen
Receptor
P504s
CK, 34βE12
p63
CK 5
Prostate Carcinoma
-
+
+
+
-
-
-
Benign Prostate
+
+
+
-/+
+
+
+
Myoepithelial Tumor: Malignant vs. Benign
CK 14
CK
Cocktail
MS Actin Calponin SM
Myosin S-100
GFAP EMA
p63
Desmin
Malignant Myoepithelioma
+
+
+
+
+
+
+/-
+
-
-
Benign Myoepithelium
+
+
+
+
+
+
+
+
+
-
Breast Carcinoma
CK 14
CK 7
CK 20 ER/PR CA15-3 CA19-9
p63
CD117
CK 5
CD44
Infiltrating Ductal
Carcinoma
-
+
-
+
+
-
-
-
-
+
Adenoid Cystic Carcinoma
-
+
-
-
+
+
+
+
+
-
Reference
1. Reis-Filho JS, et al. Appl Immunohistochem Mol Morphol. 2003 Mar; 11(1):1-8.
2. Chu PG, et al. Histopathology. 2001 Jul; 39(1):9-16.
3. Chu PG, Weiss LM. Histopathology. 2001 Nov; 39(5):455-62.
102
